Novartis Files Public Knowledge-based Application For Approval Of Aredia For Osteogenesis Imperfecta In Japan
This article was originally published in PharmAsia News
Executive Summary
Novartis Pharma submitted a public knowledge-based application for the approval of the bone resorption inhibitor Aredia (pamidronate) for the treatment of osteogenesis imperfecta in Japan.